Join Growin Stock Community!

Abbott laboratories(ABT.US AI Earnings Summary)

US StockHealthcare
No presentation for ABT

ABT AI Earnings Summary (In-Depth)

Last updated: 2026-10-21 (US time)

2026 Q3

Core Highlights

  • Stock Price Reaction: ABBOTT LABORATORIES released its Q3 earnings before the U.S. market open on October 21, 2026. Although EPS met expectations and revenue slightly exceeded them, on earnings day, 10/21, the stock closed at $100.51, down 1.89% from the 10/20 close of $102.45. This was driven by the company lowering its full-year organic sales growth forecast to approximately 6% and announcing plans to spin off its Nutrition business by the end of 2027.
  • Market Expectations: Adjusted EPS for the quarter was $1.42, matching the $1.42 TradingView pre-earnings market expectation; revenue of $13.01B was about 0.2% above the $12.99B market expectation. Comparable sales growth reached 7%, also in line with the company's own guidance.
  • Previous Guidance: The company's adjusted EPS guidance for this quarter was $1.38 to $1.46. The actual result of $1.42 sat at the midpoint of this range, representing a solid performance.
  • In One Sentence: Revenue and profit met expectations, but the company lowered its full-year sales growth forecast to ~6% and announced a spinoff of its Nutrition business by late 2027, and the stock closed down 1.89% on earnings day.

Quarterly Highlights

The announcement of the Nutrition spinoff is the major strategic event of the quarter, while the financial figures themselves showed steady acceleration.

  1. Acceleration in Top and Bottom Lines: In 2026 Q3, comparable sales grew by 7% and adjusted EPS reached $1.42. Both metrics accelerated compared to the first half of the year. EPS met the company's guidance ($1.38–$1.46) and market expectations (CFO Phil Boudreau stated it was "in line with our guidance and the market expectation"). Adjusted gross margin increased by 140 basis points year-over-year to 57.2%, and adjusted operating margin reached 23.4%, up 40 basis points.

  2. Nutrition Business Spinoff: Abbott Laboratories (ABT) announced plans to spin off its Nutrition business into an independent, publicly traded company via a tax-free stock distribution, expected to be completed by the end of 2027. The new company, with annual sales of ~US$8.5B, ~16,000 employees, and 14 manufacturing plants, will be the world's largest pure-play healthy nutrition company and is expected to qualify for the S&P 500. CEO Robert Ford noted that post-spinoff, ABT's sales growth is expected to accelerate by 50–100 basis points, gross margins to improve by over 200 basis points, and operating margins to rise by ~100 basis points.

  3. Electrophysiology (EP) Growth Phase: The Medical Devices segment grew 8% overall. Within it, EP (excluding Left Atrial Appendage, or LAA, products) saw global growth of ~14%–19%, with the US exceeding 20% (ex-LAA). The Volt PFA catheter (pulsed field ablation) achieved a full market launch in mid-August, driving 25% growth in Europe for Q3. The TactiFlex Duo catheter (which switches between RF and PFA energy) received early FDA approval in September, with a full US launch set for Q4.

  4. High Growth in Cancer Diagnostics & Ahead-of-Schedule Integration: The Cancer Diagnostics segment grew 14% year-over-year. Cologuard screening continued to grow at ~14%–16%, with new users exceeding expectations and the re-screening funnel expanding. A first-of-its-kind blood-based colorectal cancer test launched in late September, making ABT the only company offering both stool and blood-based screening. The Exact Sciences integration is ahead of schedule; operating margins improved from slightly above zero pre-acquisition to ~17%–19% by the end of the quarter.

  5. Double-Digit Growth in Rhythm Management: Adoption of the AVEIR leadless pacemaker in both single and dual-chamber markets continued to expand, driving 10% growth in the Rhythm Management segment across US and international markets. CEO Ford emphasized that innovation is transforming this traditionally low-growth market into a consistent growth engine.

  6. Nutrition Segment Reclaims Leadership: Nutrition grew 5% year-over-year, with positive growth across all four categories (US Pediatric, International Pediatric, US Adult, International Adult). Pediatric growth was 9% (US Pediatric 11%), benefiting from WIC contract wins earlier this year; ABT has regained leadership in both WIC and non-WIC markets. Adult nutrition grew 2% (US Adult 3.5%), with retail consumption data continuing to improve. Revenue increased by over $100M quarter-over-quarter.

  7. Established Pharmaceuticals (EPD) Sustains High Single-Digit Growth: EPD grew 8.5%, with double-digit growth in several Asian, Latin American, and Middle Eastern countries, reflecting structural resilience in emerging market healthcare demand. CEO Ford noted that EPD has maintained stable growth of 7.5%–8% every quarter for five years, and the biosimilar pipeline is entering a new growth cycle.

  8. FDA Approval for Libre Duo: The Continuous Glucose Monitoring (CGM) segment grew 8%. In August, the FDA approved Libre Duo—the world's first dual-function sensor to monitor both glucose and ketones. It is expected to launch in the US in December, providing diabetes patients a new way to monitor ketones without traditional blood or urine tests.

Sign up for free!

You can sign up for free or Log In to read more information!

Free In-Depth for popular US stocks:

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer